PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.01 | -0.00 | -0.12 |
| FCF Yield | -35.48% | -35.72% | -17.23% | -4.53% |
| EV / EBITDA | -1.70 | -5.04 | 1.06 | -3.26 |
| Quality | ||||
| ROIC | -837.40% | -48.75% | 228.67% | -45.98% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.62 | 2.05 | -0.23 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -26.11% | 75.42% | 66.16% | 79.22% |
| Free Cash Flow Growth | 54.35% | -5.93% | -219.79% | 40.31% |
| Safety | ||||
| Net Debt / EBITDA | 0.15 | 1.14 | -0.39 | 1.48 |
| Interest Coverage | -142.66 | -74.28 | 112.17 | -128.72 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |